DiaCarta Q&A: Liquid Biopsy for Early Cancer Detection
DiaCarta is initiating a large-scale clinical development program, which will monitor cfDNA levels to determine early treatment outcomes of systemic therapy in all types of stage IV cancer.
Tag
biomarker
Tech Licensing: (352) 392-8929
The Hub: (352) 294-0885
747 SW 2nd Avenue
Gainesville, FL 32601
Sid Martin Biotech: (386) 462-0880
12085 Research Drive
Alachua, FL 32615